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Abstract
Background: Three dimensional (3D) growths of cancer cells in vitro are more reflective of in situ cancer cell
growth than growth in monolayer (2D). The present study is designed to determine changes in protein and
phosphoprotein that reflect adaptation of tumor cells to 3D as compared to 2D. Since relative hypoxia is a
common feature of most solid tumors, the present study also aims to look at the impact of transition from
normoxia to hypoxia in these two growth conditions.
Results: Using reverse-phase protein arrays, we compared levels of 121 different phosphorylated and non-
phosphorylated proteins in 5 glioma and 6 adenocarcinoma lines under conditions of 3D and monolayer culture in
normoxia and hypoxia. A three-way analysis of variance showed levels of 82 antibodies differed between media
(2D vs. 3D) and 49 differed between treatments (hypoxia vs. normoxia). Comparing 2D to 3D growth, 7 proteins
were commonly (i.e., > 50% of tumors) elevated in 3D: FAK, AKT, Src, GSK3ab, TSC2, p38, and NFbp65. Conversely,
7 other proteins are commonly decreased: ATRIP, ATR, b-catenin, BCL-X, cyclin B1, Egr-1, and HIF-1a. Comparing
normoxia to hypoxia, only NCKIPSD was commonly elevated in hypoxia; 6 proteins were decreased: cyclin B1,
4EBP1(Ser65), c-Myc, SMAD3(Ser423), S6(Ser235), and S6(Ser240). Hypoxia affected glioma cell lines differently from
adenocarcinoma cell lines: 8 proteins were increased in gliomas (BAX, caspase 7, HIF-1a, c-JUN, MEK1, PARP 1
cleaved, Src, and VEGFR2) and none in adenocarcinomas.
Conclusions: We identified subsets of proteins with clearly concordant/discordant behavior between gliomas and
adenocarcinomas. In general, monolayer to 3D culture differences are clearer than normoxia to hypoxia differences,
with anti-apoptotic, cytoskeletal rearrangement and cell survival pathways emphasized in the former and mTOR
pathway, transcription, cell-cycle arrest modulation, and increased cell motility in the latter.
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Background
Cancer growth and invasion reflect many genetic and
molecular events. These changes cannot be easily
defined in situ, because (a) many factors are difficult to
reproduce outside the host and (b) simplifications made
to define variables with precision can create artifacts. In
this and a prior study [1] we address a part of this
problem. Specifically, we attempt to separate results due
to a biological change of interest, the transition from
normoxia to hypoxia, from those potentially induced by
a simplification of the measurement process, growth in
monolayer instead of in three dimensional cultures (3D).
We have made other simplifications (e.g., using cell
lines as opposed to primary cultures), so we are not per-
fectly “mimicking” disease conditions. Rather, we are
focusing on effects of one specific simplification and
outlining an approach that could be used more widely.
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tumor growth is based on the premise that all tumors,
at some time, exhibit reduced oxygen delivery to the
respiring neoplastic and stromal cells. This can be
microscopic or macroscopic but can lead to proteome
changes in neoplastic and stromal cells leading to
impaired neoplastic growth through molecular mechan-
isms, resulting in cellular quiescence, differentiation,
apoptosis, and necrosis [2,3] and activation of genes,
transcription factors, proteins, and cytokine signals that
can lead to regional tumor defensive strategies such as
angiogenesis, anaerobic glycolysis, locomotion (invasion/
metastasis), as well as tumor-specific survival strategies
of apoptosis/autophagy [4,5]. These hypoxia-induced
changes have presented challenges for cytotoxic che-
motherapy and, likely, will do so for many targeted
therapies. In addition, hypoxia diminishes the effective-
ness of radiation therapy, in many cases, more for glio-
mas than for adenocarcinomas [6,7]. Thus, we hoped
that being able to compare and contrast protein and
phosphoprotein changes in glioma and adenocarcinoma
cells might help design better treatment strategies for
gliomas in the future.
The importance of studying protein changes in 3-
dimensional (3D) growth is also important since a fea-
ture of malignant cells is their ability to grow in 3-
dimensions (3D) as spheroids and colonies. This obser-
vation has led to greater study of tumors in 3D, as it is
closer to in situ growth [8-11] even though it lacks
many of the supporting extracellular systems (e.g.,
endothelial cells and capillaries, supporting matrices,
cytokines, etc.). In addition, it has been observed that
cancer cell lines grown in 2D and 3D culture respond
differently to radiation and cytotoxic drugs [12-14].
Why do cell lines exhibit this differential behavior? Oxy-
genation of tumor cells also varies with 3D growth as
cells grow distant from oxygen and nutrients, whether
tumor cells are in 3D culture [15,16] or part of an in
situ tumor [3,7,17,18]. Most studies of hypoxia in tumor
cells have utilized 2D cultures [19,20].
In this study we begin to address the following ques-
tions. What protein and phosphoprotein changes reflect
adaptations of tumor cells to 3D growth compared to
2D growth? What changes reflect adaptations from nor-
moxia to hypoxia? Do tumor cells from high-grade
glioma cell lines respond differently to 3D growth than
adenocarcinoma cell lines?W h e ne x p o s e dt or e l a t i v e
hypoxic (aka microaerophilic) conditions, are changes in
protein and phosphoprotein levels more affected by
growth in 3D culture than they are by hypoxia?
In this study, we examine levels of 121 phosphorylated
a n dn o n - p h o s p h o r y l a t e dp r o t e i n su s i n gr e v e r s e - p h a s e
protein array (RPPA) [1] technology. We examine these
levels in eleven cell lines (including both gliomas and
adenocarcinomas) under all combinations of media (2D
and 3D) and growth conditions (normoxia and hypoxia),
allowing us to properly relate changes to causes.
Results and discussion
Analysis using ANOVA (Three-Way Analysis of Variance)
Our qualitative findings can be inferred from the p-
value plots presented in Figure 1. Visual inspection of
the distributions of p-values obtained for each ANOVA
term (treatment, growth condition, cell line of origin,
potential interaction between treatment and growth
condition) clearly showed numbers of small p-values far
greater than we would expect by chance for treatment,
medium, and cell line, but not for the treatment-med-
ium interaction (Figure 1). The cell line term is a nui-
sance factor, so we focused our attention on the
individual effects of treatment and medium.
To account for multiple testing, we fit both distribu-
tions of p-values with beta-uniform mixture (BUM)
models
5 and chose cutoffs to target false discovery rates
(FDRs) of 5% and 1%. The extent of change (the height
of the peak) is much more extensive for the shift from
2D to 3D than for the shift from normoxia to hypoxia.
The corresponding plot for interaction terms here
shows just a few significant alterations, suggesting that
assessments of changes due to oxygenation conditions
made in 2D are largely preserved in 3D, answering our
primary question. However ,t h ea m o u n to fc h a n g ew e
see associated with the 2D-to-3D transition is so large
that we feel quite uneasy about generalizing measure-
ments from 2D in general without explicit testing. To
determine what changes were “robust,” we trichoto-
mized residual terms for each effect (after correcting for
others) by assigning scores of 1 (top 25%), -1 (bottom
2 5 % ) ,a n d0( a l lo t h e r s ) ,a n ds u m m e dt h e s ev a l u e sb y
cell line or antibody, which is an approach we found
useful in an earlier study [1]. We also used these sums
to look for differences between gliomas and adenocarci-
nomas. No proteins showed a significant interaction
between culture conditions and treatment in any cell
line at the 5% FDR.
Comparison of 2D and 3D Growth
The comparisons that follow are the product of an
aggregate analysis across 11 cell lines and 4 growth con-
ditions focusing on the protein differences between 2D
and 3D culture conditions. According to the BUM plots,
82 proteins were significantly different at a 5% FDR. Fig-
ures 2 and 3 show (a) the 3D-2D (change from 2D to
3D) sum scores with a focus on protein values from the
ANOVA for proteins with p-values < 0.05, (b) the asso-
ciated estimated fold changes in expression (negative
values indicate expression was higher in 2D cultures),
and (c) trichotomized scores for individual protein
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Page 2 of 13samples, broken down to show results for individual
gliomas or adenocarcinomas (for all values see Addi-
tional file 1). Figures 2 and 3 entries are sorted by fold
change, and overall sums of the robust scores by cell
line are given at the bottom of the table. We also show
the aggregate glioma and adenocarcinoma behavior by
indicating whether the robust scores in a category
showed consistent values for at least 50% of the samples
examined. The glioma cell line most consistently chan-
ged by 3D-2D growth conditions was U87, with an aver-
age sum score across hypoxic/normoxic conditions of
-18.5((-17+-20)/2) indicating protein and phosphopro-
tein down-regulation as conditions shift from 2D to 3D.
By contrast, U251 ((14+-1)/2) and LN229 ((14+-1)/2)
both showed general up-regulation of proteins when
moving from 2D to 3D, though these gains were con-
centrated in the hypoxic conditions. For the adenocarci-
nomas, SKOV3 showed the greatest down regulation,
with an average sum score of-20 ((-22+-18)/2), while
MDA231 showed the greatest up regulation, with an
average sum score of 19((14+24/2)).
Qualitative examination of Figures 2 and 3 shows that
as a group, adenocarcinoma cell lines had 1.6 times
more -1 sum scores and 2.0 times more +1 sum scores
than glioma cell lines. However, approximately 32 pro-
teins showed parallel changes in adenocarcinoma and
glioma cell lines. The breakdown of these 32 proteins
that moved in parallel in > 50% of glioma and > 50% of
adenocarcinoma cell lines are as follows:
1) Levels of 7 proteins were lower in 3D than 2D
cultures for the two groups: ATRIP, ATR, b-catenin,
BCL-X, cyclin B1, Egr-1, and HIF-1a;
2) 18 proteins showed no grossly consistent differ-
e n c e s :A I B 1 ,A R ,A T R ( S e r 4 2 8 ) ,B C L 2 ,B C L - X L ,c a s -
pase 3, EGFR(Tyr992), 4EBP1(Ser65), LKB1,
MGMT, p85 PI3K, p90RSK(Thr359), PCNA, PTCH,
Rab25, Stat6(Tyr694), Stat5(Tyr694) and YY1; and
3) Levels of 7 proteins were higher in 3D than 2D
cultures: AKT, FAK, GSK3ab(Ser21), NFbp65
(Ser536), p38(Thr180), c-Src(Tyr418), and TSC2
(Thr1462).
In addition to the protein changes above, differences
were seen between glioma and adenocarcinoma cell
lines grown in 3D and 2D cultures. In glioma cell lines,
protein or phosphoprotein levels of Stat3(Thr727) and
COX2 were also higher in 3D cultures, whereas in ade-
nocarcinoma lines, additional protein increases were
seen in 14-3-3-Z, TAU, ACC(Ser79), annexin, caspase 7,
FOXO3, MAPK(Thr202), p70S6K, B-RAF, PARP, and
PDK1(Ser241). In glioma cell lines, lower protein level
in 3D cultures was seen only for cyclin D1, MSH2, Rb,
S6(Ser235), and S6(Ser240), whereas in adenocarcinoma
lines, lower levels were seen in ER(Ser118), FOXO3a
(Ser318), c-Jun(Ser73), c-Jun, c-Myc(Thr58), c-Myc, Rb
(Ser807), SMAD3(Ser423), Src(Tyr527), Stat3, and
VEGFR2.
A.
B.
C.
Figure 1 Histogram showing the distribution of p-values from
the feature-by-feature three-way ANOVAs. Superimposed curves
represent fits of the BUM models for (A) medium (2D and 3D), (B)
treatment (hypoxia and normoxia), and (C) interaction between
medium and treatment.
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Page 3 of 13Comparison of Hypoxic and Normoxic Growth
The comparisons that follow are the product of an
aggregate analysis across 11 cell lines and 4 growth con-
ditions focusing on the protein differences between nor-
moxia and hypoxia culture conditions. On the basis of
the BUM plots, 50 proteins were significantly different
in conditions of hypoxic and normoxic growth at a 5%
FDR. Figure 4 focuses on (a) protein values from the
ANOVA for proteins with p-values < 0.05, (b) the asso-
ciated estimated fold change (negative values indicate
that expression was higher in normoxic cultures), and
(c) trichotomized scores for individual samples, broken
down to show results for individual glioma and
adenocarcinoma cell lines (for all values see Additional
file 2). Figure 4 entries are sorted by fold change, and
overall sums of the robust scores by cell line are given
at the bottom. We have also shown aggregate glioma
and adenocarcinoma behavior by indicating whether the
robust scores in a category showed consistent values for
at least 50% of the samples examined. Figure 4 shows
that no glioma cell line showed a consistent decrease in
sum scores between normoxic and hypoxic cultures, but
some did increase. Proteina n dp h o s p h o p r o t e i ns u m
scores were higher in hypoxic cultures for U87, LN229,
and U251 cells, with sums of +12, +10.5, and +9, respec-
tively. For the adenocarcinoma cell lines, SKOV3 had
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GL & AC: Up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AKT  0  1  1  1  0  0  1  0  1  1  1  1  1  1  1  0  1  1  -1  0  0  1  1  1  1.4 
FAK  0  -1  1  1  1  1  1  0  0  0  1  1  1  0  1  0  1  1  1  0  0  1  0  1  1.2 
GSK3α/β(Ser21)  1  -1  1  1  1  1  1  1  1  1  1  1  1  1  1  0  0  0  1  1  1  1  1  1  1.7 
NFkBp65(Ser536)  1  0  1  1  1  0  1  1  1  0  1  1  1  1  1  1  0  0  0  1  1  1  1  1  1.7 
p38(Thr180)  1  -1  1  1  1  1  1  1  1  0  1  0  0  1  1  1  0  0  0  1  1  1  1  1  1.7 
Src(Tyr418)  0  0  1  1  1  1  1  0  1  1  1  1  1  0  1  0  1  1  1  1  1  1  -1  1  1.7 
TSC2(Thr1462)  0  0  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1.7 
GL & AC: Down                                                                            
ATR  -1  0  -1  -1  -1  -1  -1  0  -1  0  -1  -1  -1  -1  -1  -1  0  0  0  -1  -1  -1  -1  -1  -1.5 
ATRIP  0  1  -1  -1  -1  -1  0  0  -1  -1  -1  0  -1  -1  -1  -1  -1  -1  0  -1  -1  -1  -1  -1  -1.4 
BCL-X  0  0  -1  -1  -1  -1  -1  -1  0  0  -1  0  1  -1  -1  -1  -1  0  -1  -1  -1  0  0  -1  -1.4 
Beta-catenin  0  0  -1  -1  -1  0  -1  -1  -1  -1  -1  0  0  -1  -1  -1  -1  -1  0  -1  -1  -1  1  -1  -1.7 
Cyclin B1  0  0  -1  -1  -1  -1  -1  1  -1  -1  -1  -1  -1  -1  -1  -1  -1  1  0  -1  -1  1  1  -1  -1.6 
Egr-1  0  1  -1  -1  -1  -1  -1  0  -1  0  -1  -1  0  -1  -1  -1  -1  0  -1  -1  -1  0  0  -1  -1.4 
H1F-1α  -1  0  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  1  -1  -1  -1  0  -1  0  -1  -1  -1  -1  -1  -2.8 
Neutral scores                                                                            
4EBP1(Ser65)  0  -1  0  0  0  -1  -1  0  0  0  0  0  -1  0  0  0  0  0  -1  -1  -1  0  0  0  -1.2 
AIB1  0  -1  0  0  0  0  -1  0  -1  0  0  0  0  -1  0  -1  0  0  0  -1  -1  -1  0  0  -1.2 
AR  0  0  0  0  -1  -1  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  -1  0  0  -1.1 
ATR(Ser428)  0  0  -1  -1  0  0  1  0  0  0  0  0  0  0  0  -1  -1  0  0  -1  0  0  -1  0  -1.1 
BCL2  -1  0  0  0  -1  -1  0  0  0  0  0  -1  -1  0  0  0  0  0  -1  0  0  -1  -1  0  -1.2 
BCL-XL  0  0  0  0  -1  -1  0  0  0  0  0  0  0  0  0  0  0  0  -1  -1  -1  0  -1  0  -1.2 
Caspase 3  0  0  0  0  0  0  1  0  1  0  0  1  0  0  0  0  0  0  1  0  0  0  -1  0  1.1 
EGFR(Tyr992)  0  0  0  0  0  -1  0  0  1  0  0  0  0  0  0  0  0  0  0  1  1  0  -1  0  1.1 
LKB1  0  1  0  0  0  0  0  0  0  0  0  1  1  0  0  0  0  0  0  0  0  1  0  0  1.1 
MGMT  0  1  0  0  0  0  1  0  1  0  0  1  1  1  1  0  0  0  1  0  0  0  0  0  1.2 
p85 PI3K  0  1  0  0  0  0  1  0  1  0  0  0  0  1  1  0  0  0  0  1  1  1  0  0  1.2 
p90RSK(Thr359)  0  0  0  0  0  -1  0  0  0  0  0  0  0  0  0  0  -1  0  0  -1  -1  -1  -1  0  -1.1 
PCNA  -1  0  0  0  -1  -1  -1  0  0  0  0  0  0  0  0  0  0  0  0  -1  0  0  0  0  -1.1 
PTCH  0  0  0  0  0  0  1  0  0  -1  0  0  0  0  0  0  -1  0  0  0  0  0  -1  0  -1.1 
Rab25  0  0  0  1  0  0  1  -1  1  0  0  0  1  0  1  0  0  0  0  0  1  0  -1  0  1.1 
STAT5(Tyr694)  0  0  0  1  0  0  1  0  0  0  0  0  0  0  1  0  0  0  -1  1  1  -1  0  0  1.4 
STAT6(Tyr694)  0  0  0  1  0  0  1  0  0  0  0  0  1  1  1  0  0  0  0  1  1  0  0  0  1.3 
YY1  -1  1  -1  0  0  0  0  0  0  0  0  0  0  -1  0  0  0  0  0  -1  -1  -1  0  0  -1.2 
Figure 2 Protein changes from ANOVA of 3D-2D (monolayer to 3D) medium by cell line whether normoxic or hypoxic conditions for
proteins with p-value < 0.05. Proteins are ordered from based on the FC (fold change) and scored -1, 0, or +1, depending on quartile
distribution of raw antibody difference values (-1, blue, lowest quartile; +1, red, highest quartile; 0, green, others). Also shown is the score when
> 50% of the total for glioma (GL; 6/10) and adenocarcinoma (AC; 7/12) values move in the same direction. The data is divided into six
groupings based on > 50% score (+1, -1, and 0) for gliomas (GL) and adenocarcinomas (AC) together and separately as well as neutral and ill-
defined scores.
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GL-specific                                                   
COX2  0  -1  1  1  1  1  1  0  1  1  1  1  1  1  1  0  1  0  -1  0  1  1  0     1.5 
Cyclin D1  1  -1  -1  -1  -1  -1  0  0  -1  0  -1  0  0  0  0  0  0  0  -1  0  0  -1  0  0  -1.2 
MSH2  -1  0  0  0  -1  -1  -1  0  -1  -1  -1  0  0  0  0  0  1  0  1  -1  -1  0  0  0  -1.1 
Rb  0  1  -1  -1  -1  -1  -1  0  -1  0  -1  0  0  -1  0  0  0  0  -1  -1  -1  0  0  0  -1.3 
S6(Ser235)  0  -1  -1  -1  -1  -1  -1  0  0  -1  -1  -1  -1  0  -1  1  0  -1  -1  0  -1  0  1     -1.6 
S6(Ser240)  1  -1  -1  -1  -1  0  -1  0  0  -1  -1  -1  -1  0  -1  1  1  -1  -1  0  -1  1  1     -1.5 
STAT3(Thr727)  0  1  1  1  0  0  1  1  1  1  1  1  0  0  1  0  0  1  1  0  0  0  0  0  1.2 
AC-specific                                                                            
14-3-3-Z  0  -1  1  1  0  0  1  0  1  0     1  1  1  1  1  1  0  0  0  0  1  0  1  1.2 
ACC(Ser79)  0  -1  0  0  0  0  0  1  1  1  0  0  1  1  1  0  1  0  1  0  0  1  1  1  1.2 
Annexin 1  -1  -1  1  1  0  -1  1  -1  0  -1     1  1  1  1  1  1  0  -1  1  1  0  -1  1  1.4 
B-RAF  0  -1  0  0  0  0  1  0  1  0  0  1  1  1  1  0  1  1  1  0  0  1  1  1  1.3 
Caspase7  -1  0  1  1  0  0  1  0  1  0     1  1  1  1  1  1  1  1  1  1  1  -1  1  1.5 
EGFR  0  0  0  0  -1  0  -1  0  0  0  0  -1  -1  -1  -1  -1  -1  -1  1  -1  -1  0  -1  -1  -1.4 
ER(Ser118)  1  1  -1  -1  0  1  -1  0  -1  -1     1  1  -1  -1  -1  -1  -1  -1  -1  -1  0  -1  -1  -2.3 
FOXO3  0  0  1  1  0  0  1  0  1  1     1  1  1  1  1  1  0  0  1  1  0  0  1  1.4 
FOXO3α(Ser318)  0  0  -1  -1  0  0  0  0  0  0  0  -1  0  -1  -1  -1  -1  -1  -1  -1  -1  0  0  -1  -1.3 
Jun  1  1  -1  -1  0  0  -1  0  -1  -1     -1  -1  -1  -1  0  -1  -1  -1  -1  -1  -1  -1  -1  -1.4 
Jun(Ser73)  1  1  -1  -1  0  0  -1  1  0  0     -1  -1  -1  0  0  -1  0  -1  -1  -1  -1  -1  -1  -1.2 
MAPK(Thr202)  0  -1  1  1  0  -1  1  1  0  -1     1  1  0  1  1  1  1  -1  1  1  1  -1  1  1.5 
Myc  1  1  -1  -1  -1  -1  0  1  0  0     -1  -1  -1  -1  -1  -1  0  -1  -1  -1  -1  -1  -1  -1.8 
Myc(Thr58)  0  1  0  0  -1  -1  0  0  1  0  0  0  0  -1  -1  0  -1  0  0  -1  -1  -1  -1  -1  -1.2 
p70S6K  0  0  0  0  0  0  1  0  1  0  0  1  1  1  1  1  1  1  1  0  0  1  1  1  1.3 
PARP 1 cleaved  -1  -1  1  0  0  0  1  0  1  0     1  1  1  1  1  1  1  1  1  1  1  -1  1  1.6 
PDK1(Ser241)  0  0  0  0  0  0  0  0  1  0  0  1  1  1  1  1  0  0  0  0  0  1  1  1  1.1 
Rb(Ser807)  1  1  -1  -1  0  0  0  1  -1  -1     -1  0  -1  0  -1  -1  0  -1  -1  -1  -1  1  -1  -1.4 
SMAD3(Ser423)  0  1  -1  -1  -1  0  -1  0  -1  0     -1  1  -1  -1  0  0  1  -1  -1  -1  -1  -1  -1  -1.3 
Src(Tyr527)  0  1  -1  0  0  0  0  0  0  1  0  -1  -1  -1  1  -1  -1  0  0  -1  -1  -1  -1  -1  -1.2 
STAT3   0  1  0  -1  0  0  1  0  0  0  0  0  1  -1  0  -1  -1  0  -1  -1  -1  0  -1  -1  -1.2 
TAU  -1  1  1  1  -1  -1  -1  -1  0  1     1  1  1  1  1  1  1  1  1  1  1  -1  1  1.2 
VEGFR2  1  0  -1  -1  0  1  1  1  -1  -1     -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  1  1  -1  -1.3 
Ill-defined                                                                             
ATM  -1  1  0  0  0  -1  1  -1  1  1     1  1  -1  0  1  1  1  0  0  0  0  0     1.1 
BAD(Ser112)  -1  0  0  0  0  -1  1  0  1  1     0  1  1  1  1  0  0  0  0  0  1  -1     1.1 
BIM  -1  1  0  0  -1  -1  -1  -1  0  0     0  0  0  -1  0  0  -1  1  -1  -1  0  -1     -1.2 
CD31  -1  -1  0  0  1  0  0  -1  0  0  0  1  1  1  0  0  0  0  0  1  1  0  -1     1.1 
Collagen VI  0  1  -1  -1  0  0  0  -1  0  0  0  1  1  0  -1  0  -1  0  0  -1  -1  0  -1     -1.1 
eLF4E  -1  -1  1  0  0  -1  0  0  1  0     0  0  1  1  1  1  0  0  0  0  1  0  0  1.1 
ETV6  -1  -1  0  0  0  0  -1  -1  -1  0     1  1  0  0  -1  -1  1  1  0  -1  -1  -1     -1.1 
GSK3α/β  0  -1  1  1  0  -1  0  0  1  0     0  0  1  1  0  0  0  0  -1  0  1  1  0  1.1 
HER2(Tyr1248)  0  0  -1  0  1  1  1  0  0  1     0  1  0  0  -1  0  1  0  1  1  1  0     1.3 
IRS1(Ser307)  0  0  -1  -1  0  0  0  -1  -1  -1     1  0  0  -1  -1  -1  1  0  -1  -1  -1  0     -1.3 
MEK1  1  0  1  0  0  0  1  1  1  0     1  1  1  0  0  1  0  -1  0  0  1  1     1.4 
N-cadherin  0  1  -1  -1  0  0  0  -1  0  0     0  0  0  0  0  0  0  0  -1  -1  0  -1  0  -1.1 
NCKIPSD  1  1  0  -1  0  0  1  0  1  0     1  1  1  0  0  0  0  0  -1  0  1  0  0  1.2 
Notch 1  -1  0  -1  -1  0  0  0  -1  0  -1     0  0  0  0  -1  -1  0  0  -1  -1  0  0  0  -1.2 
p90RSK  0  0  1  0  0  1  1  0  1  1     0  0  0  0  1  0  0  0  -1  0  0  -1  0  1.1 
PKCα(Ser657)  0  0  1  1  0  -1  1  0  0  0  0  1  1  0  -1  0  0  -1  -1  -1  -1  0  -1     -1.1 
PTEN  0  0  0  0  -1  -1  1  -1  1  1     1  1  1  1  0  1  0  -1  0  0  0  0     1.1 
RAD51  0  0  0  0  -1  -1  0  0  0  0  0  -1  -1  -1  0  0  0  0  -1  -1  -1  0  0     -1.2 
Spermine synthase  0  1  1  1  -1  0  0  1  0  0     0  1  1  0  1  1  0  0  0  0  1  0  0  1.2 
XIAP  0  0  0  0  -1  0  0  0  0  0  0  0  0  -1  -1  0  0  -1  1  -1  -1  0  -1     -1.2 
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Figure 3 Protein changes from ANOVA of 3D-2D (monolayer to 3D) medium by cell line whether normoxic or hypoxic conditions for
proteins with p-value < 0.05. Proteins are ordered from based on the FC (fold change) and scored -1, 0, or +1, depending on quartile
distribution of raw antibody difference values (-1, blue, lowest quartile; +1, red, highest quartile; 0, green, others). Also shown is the score when
> 50% of the total for glioma (GL; 6/10) and adenocarcinoma (AC; 7/12) values move in the same direction. The data is divided into six
groupings based on > 50% score (+1, -1, and 0) for gliomas (GL) and adenocarcinomas (AC) together and separately as well as neutral and ill-
defined scores. The Sum Score at the bottom of the figure is the summed values for columns in figures 2 and 3.
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Page 5 of 13the most down regulation with an average sum score of
-22.5 [(-13+-32)/2], while OVCAR5 and MDA231
showed the greatest up regulation, with average sum
scores of 13.5 and 10, respectively.
Qualitative examination of Figure 4 shows that, as a
group, glioma cells lines had 1.7 times more -1 sum scores
and 10 times more +1 sum scores than adenocarcinoma
cell lines. However, 17 proteins showed parallel changes in
adenocarcinoma and glioma cell lines, as follows:
1) Levels of 6 proteins were lower in hypoxic condi-
tions than in normoxic conditions in the two groups:
cyclin B1, 4EBP1(Ser65), c-Myc, SMAD3(Ser423), S6
(Ser235), and S6(Ser240);
2) 10 proteins showed no grossly consistent differ-
ences: caspase 3, EGFR(Tyr1173), elF4E, FAK, JNK2,
MGMT, PDK1, spermine synthetase, TSC2
(Thr1462), and VASP; and
3) 1 protein was higher in hypoxic cultures:
NCKIPSD.
In addition to the protein changes reported above, dif-
ferences were seen between glioma and adenocarcinoma
cell lines grown in hypoxia and those grown in nor-
moxia. In glioma cell lines, protein or phosphoprotein
levels were also higher for BAX, caspase 7, HIF-1a,c -
JUN, MEK1, cleaved PARP, Src(Tyr527), and VEGFR2,
whereas no additional protein increases were seen in
adenocarcinoma lines. In glioma cell lines, hypoxia
caused declines in the expression of AR, ATR(Ser428),
cyclin D1, and Rb(Ser807), whereas no additional pro-
tein decreases were seen in adenocarcinoma lines.
Relevance of Protein Changes
In order to better understand the implications of the
protein changes we observed, we used the Weizmann
Institute of Science site http://www.genecards.org, Cell
Signaling Technology http://www.cellsignal.com/, and
TOCRIS Bioscience http://www.tocris.com/ to annotate
the gene-associated proteins studied. Our interpretation
of protein interactions and their implications is subject
t oac a v e a t :w eo n l yh a v ea ni n c o m p l e t eu n d e r s t a n d i n g
of the non-linear interactions among signaling proteins,
and, therefore, can only surmise functional significance
from the protein changes we observed.
2D to 3D Changes Overall
While there are a number of ways that our data could
be analyzed and interpreted, we analyzed the aggregate
d a t af o r2 Dt o3 Dc u l t u r er e g a r d l e s so fw h e t h e rc e l l s
w e r eg r o w ni nn o r m o x i ao rh y p o x i a .F r o mt h e s ed a t a
we concluded that the majority of cancer cell lines share
some proteins that are increased to enable 3D growth
and proteins that are reduced to minimize non-vital cell
functions and focus. For the sake of discussion, and
using available pathway analyses, we propose some rela-
tionships for the major protein changes observed for
both glioma and adenocarcinoma cell lines (Figure 5).
Increasing AKT can tend to decrease apoptosis and
increase insulin stimulated protein synthesis by phos-
phorylating TSC2 (Thr1462) and activating mTOR sig-
naling and phosphorylating 4E-BP1 and RPS6KB1.
Increasing FAK, a substrate for c-Src, is important in
cell migration and mobility, and appears to be important
in shifting cancer cells from 2D to 3D growth. Similarly,
increases in GSK3a/b should help in cell division and
motility through its ability to phosphorylate signaling
proteins, transcription factors, and structural proteins,
all of which are needed to support 3D growth. Increases
in NFb and p38, a MAP kinase family member, have
effects on proliferation and transcriptional regulation
through their ability to respond to cytokines and extra-
cellular environmental stress, conditions that may be an
advantage to cancer cells seeking to achieve 3D growth.
Contra wise, the proteins levels that decreased suggested
that these cancer cells did not need to protect them-
selves against DNA damage (ATR and ATRIP) or apop-
tosis (BCL-X and cyclin B1) or maintain cell adhesion
on a plastic surface (b-catenin). The paradoxical
decrease in transcriptional control of mitogenesis and
differentiation (Egr-1) and HIF-1a is problematic. Even
if we look at 2D to 3D growth separately for normoxia
and hypoxia (see Additional File 1 for details) HIF1-a
paradoxically decreased. Since HIF-1a did go up in the
glioma lines in response to the shift from normoxia to
hypoxia, it is possible that cells adapting to 3D growth
in AlgiMatrix 3D Culture System or as a normal survival
mechanism reduce HIF-1a protein or that HIF-1a
degradation occurred under when cells were grown in
the AlgiMatrix 3D Culture System in a manner similar
to the ubiquitination seen with hypoxia-associated factor
[21]. Thus, while we are confident of our finding, we are
not sanguine as to its basis at this time since we did not
measure the level of HIF-2a in our RPPA study. We
have made our entire database available for others to
mine (see Additional file 1 for details) in the expectation
that scientists will find these data helpful and, possibly,
better explain these findings.
2D to 3D Changes Specific to Gliomas or Adenocarcinomas
In addition to the general changes, there were glioma-
specific changes in protein levels. Increases in Stat 3
suggest that glioma cells, responding to cytokines and
growth factors, activate transcription to help establish
3D growth. Increase in inducible COX2 is known to
occur in gliomas and may, through prostanoid biosynth-
esis, enhance mitogenesis. There were also specific
changes in adenocarcinoma lines. Increases may reflect
increased signaling activities and direct effects on cell
adhesion and anchorage-independent growth (14-3-3-Z),
Levin et al. Proteome Science 2012, 10:5
http://www.proteomesci.com/content/10/1/5
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GL & AC: Up                                                                            
NCKIPSD  0  -1  0  1  1  1  0  1  1  1  1  1  1  1  1  1  0  1  0  0  -1  0  1  1  1.2 
GL & AC: Down                                                                            
S6(Ser240)  -1  1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  1  -1  -1  -1  0  -1  -1  -1  -2.3 
S6(Ser235)  -1  1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  0  -1  1  -1  -1  -1  0  -1  -1  -1  -1.9 
Cyclin-B1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  1  1  -1  0  0  -1  -1  -1  -1  -1  -1  -1  -1  -1.5 
C-Myc  1  0  -1  -1  -1  -1  -1  -1  -1  -1  -1  1  1  0  0  -1  -1  -1  -1  -1  -1  0  -1  -1  -1.3 
SMAD3(Ser423)  0  -1  -1  -1  0  -1  0  -1  -1  -1  -1  1  -1  1  -1  -1  -1  -1  0  0  -1  0  -1  -1  -1.2 
4EBP1(Ser65)  -1  1  -1  -1  -1  0  -1  -1  -1  0  -1  -1  0  -1  -1  0  0  -1  0  -1  -1  -1  -1  -1  -1.1 
Neutral scores                                                                            
Caspase3  0  0  0  0  1  0  0  1  0  1  0  0  0  0  0  0  0  0  0  0  -1  -1  1  0  1.1 
EGFR(Tyr1173)  0  0  0  0  0  1  0  1  0  1  0  0  0  0  0  1  0  1  1  0  0  0  1  0  1.2 
eLF4E  0  0  0  1  0  1  0  1  0  1  0  0  0  0  1  0  1  -1  0  0  0  -1  1  0  1.1 
FAK  0  1  0  0  1  0  0  1  0  0  0  -1  0  0  0  1  0  0  0  0  -1  -1  1  0  1.1 
JNK2  0  0  0  0  0  0  0  1  0  1  0  0  0  1  1  0  0  -1  0  0  0  0  1  0  1.1 
MGMT  0  0  0  1  0  1  0  1  0  1  0  1  0  0  0  0  0  1  -1  0  -1  0  -1  0  1.1 
PDK1   0  -1  0  0  0  1  0  1  0  1  0  0  0  0  1  0  0  0  0  -1  -1  -1  1  0  1.1 
Spermine-synthase  0  -1  0  1  1  0  0  0  0  1  0  1  0  1  1  0  0  0  0  0  0  0  1  0  1.1 
TSC2(Thr1462)  -1  -1  0  1  0  0  0  1  0  0  0  1  0  1  0  0  0  0  1  1  0  0  1  0  1.1 
VASP  0  0  0  1  0  1  0  1  0  1  0  0  1  0  0  1  0  0  0  0  -1  -1  1  0  1.1 
GL-specific                                                                            
AR  -1  -1  -1  -1  0  0  -1  -1  -1  1  -1  0  0  0  0  0  0  -1  0  0  -1  -1  -1  0  -1.1 
ATR(Ser428)  0  -1  0  -1  -1  -1  0  -1  0  -1  -1  0  1  0  -1  0  0  0  0  -1  -1  -1  -1     -1.1 
BAX  0  1  1  1  0  0  0  1  1  1  1  0  0  1  1  0  0  -1  0  -1  -1  0  1     1.1 
Caspase7  1  0  1  1  1  1  0  1  0  1  1  0  -1  1  1  0  1  0  0  0  0  -1  1     1.3 
C-JUN  1  1  -1  1  1  1  0  -1  1  1  1  1  1  1  1  -1  0  -1  -1  -1  0  1  1     1.3 
COX2  1  1  0  1  1  1  1  1  1  1  1  1  -1  0  0  0  0  -1  0  0  -1  0  1  0  1.4 
Cyclin-D1  -1  1  -1  0  -1  -1  -1  -1  -1  -1  -1  -1  0  0  0  0  -1  -1  0  -1  0  0  -1  0  -1.2 
H1F-1α  1  1  1  -1  1  -1  1  -1  1  -1  1  1  -1  -1  -1  1  0  1  0  -1  -1  1  0     1.5 
MEK1  -1  1  0  1  1  1  0  1  0  1  1  1  1  -1  1  1  1  -1  -1  0  0  0  1     1.2 
PARP 1 cleaved  1  0  1  1  1  1  0  1  0  1  1  0  1  1  1  1  1  0  0  0  -1  -1  1     1.5 
Rb(Ser807)  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  -1  1  0  0  -1  -1  -1  -1  -1  0  0  1  -1     -1.4 
Src(Tyr527)  1  -1  1  0  1  1  1  1  0  0  1  1  0  1  0  0  0  0  0  0  0  -1  0  0  1.1 
VEGFR2  0  1  1  1  1  0  1  1  1  1  1  1  0  1  -1  1  0  0  0  1  -1  1  1     1.3 
Ill-defined                                                                             
14-3-3-Z  0  1  0  0  1  0  0  1  0  1  0  -1  0  0  0  1  1  0  0  0  -1  -1  1     1.1 
4EBP1  0  -1  0  0  1  1  0  0  0  1     0  0  0  0  1  1  1  0  1  -1  0  1     1.1 
BCL-XL  1  1  1  0  0  0  0  1  1  0  0  1  1  1  1  0  0  0  0  -1  -1  1  1     1.2 
CHK2(Thr68)  0  0  0  0  0  1  0  1  1  1  0  1  0  1  1  0  1  1  0  0  0  0  1     1.2 
Collagen-VI  0  0  0  1  0  1  0  1  1  0  0  0  0  1  1  0  0  -1  0  -1  -1  0  1     1.1 
EGFR  1  0  0  0  1  1  1  0  0  1     0  0  1  0  0  -1  1  0  -1  -1  0  1     1.2 
FAK(Tyr397)  0  0  0  1  0  1  0  1  1  0  0  1  0  1  0  0  1  1  0  0  -1  0  1     1.1 
FOXO3  0  0  0  1  0  0  0  1  1  1  0  1  1  1  1  0  1  0  0  0  -1  0  1     1.2 
FOXO3α(Ser318)  -1  -1  0  0  1  1  0  0  0  0  0  1  0  0  1  1  0  0  0  1  -1  1  1     1.1 
HSP70  0  0  1  1  1  0  0  1  0  1     0  0  0  1  0  0  0  0  0  -1  -1  1  0  1.1 
N-Cadherin  1  -1  0  -1  1  1  0  1  0  0     0  1  0  0  -1  0  0  0  0  0  -1  1  0  1.1 
Notch 1  1  -1  1  0  0  0  0  1  0  0  0  1  0  0  0  1  0  1  0  -1  -1  0  1     1.1 
Notch-3  0  0  1  0  1  0  0  1  0  1  0  0  -1  1  1  -1  -1  1  0  0  0  1  0     1.1 
p85 PI3K  0  -1  0  0  0  0  0  1  0  1  0  0  0  0  0  1  1  -1  0  -1  0  -1  1     1 
p90RSK  0  0  0  1  1  1  0  1  0  1     0  1  0  0  0  1  1  0  0  -1  0  1     1.2 
PCNA  1  -1  0  -1  0  0  0  -1  1  0     1  0  1  1  0  0  0  0  0  -1  1  0  0  1.1 
PTCH  0  1  1  0  0  1  0  1  -1  0     0  0  1  0  0  0  0  0  0  -1  0  1  0  1.1 
Rab25  0  0  0  0  0  0  0  1  0  1  0  0  -1  1  1  0  -1  0  0  0  -1  0  1     1.1 
STAT3   0  -1  0  1  0  0  1  1  1  0     1  1  1  0  -1  -1  -1  0  0  0  0  1     1.1 
STAT3(Thr727)  -1  -1  -1  -1  0  0  0  1  0  0     -1  0  0  -1  -1  -1  0  0  -1  -1  0  0     -1.1 
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Figure 4 Protein changes from ANOVA of the hypoxia-normoxia by cell line, whether grown in 2D or 3D conditions for proteins with
p-values < 0.05. The proteins are ordered based on the FC (fold change) and scored -1, 0, or +1 depending on quartile distribution of raw
antibody difference values (-1, blue, lowest quartile; +1, red, highest quartile;0, green, others). Also shown is the score when > 50% of the total
for glioma (GL; 6/10) and adenocarcinoma (AC; 7/12) values move in the same direction. The data is divided into five groupings based on > 50%
score (+1, -1, and 0) for gliomas and adenocarcinomas together and separately as well as neutral and ill-defined scores.
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Page 7 of 13fatty acid synthesis (ACC), mediation of growth-regu-
lated tyrosine kinases (annexin 1), regulation of MAPK/
ERK signaling (B-RAF), activation of apoptosis (caspase
7, FOXO3), and transcription regulation and prolifera-
t i o n( M A P K ) .I n t e r e s t i n g l y ,T A U ,am i c r o t u b u l i n - a s s o -
ciated protein, is differential l ye x p r e s s e di nt h en e r v o u s
s y s t e ma n dw a st h o u g h tt ob es o m e w h a tu n i q u et ot h e
nervous system, but we found higher levels of TAU in
adenocarcinoma cell lines. What this means is not clear,
but, given its effect in the nervous system, it may func-
tion to stabilize cytoskeletal proteins and be part of sig-
naling system to organize adenocarcinoma cells in a
basal-antral position for glandular functions.
Normoxia to Hypoxia Changes Overall
Transitioning from normoxia to hypoxia, only 17 pro-
teins move commonly among the glioma and adenocar-
cinoma cell lines. Interestingly, only one protein was
elevated, NCKIPSD, a protein implicated in signal trans-
duction as well as cell motility and stress fiber formation
[22-27]. A relationship of the 6 proteins that decreased
and the 1 protein that increased are depicted in Figure
6. In general, hypoxia appeared to decrease protein
synthesis through the mTOR pathway to reduce cell
cycle progression while supporting motility and migra-
tion through NCKIPSD
Normoxia to Hypoxia Changes Specific to Gliomas or
Adenocarcinomas
Glioma cell lines behave quite differently from adeno-
carcinoma cell lines when exposed to hypoxia. There
are 8 increased proteins in gliomas (BAX, caspase 7,
HIF-1a,c - J U N ,M E K 1 ,P A R P1c l e a v e dS r c ,a n d
VEGFR2) and none in adenocarcinomas (Figure 7). It
appears that gliomas are more responsive (sensitive) to
hypoxia than adenocarcinoma. Both pro-survival and
pro-apoptotic pathways are activated and a balance
between these two might determine the ultimate out-
come of the cells. The observations in glioma are con-
sistent with the literature [28-31].
However, the fact that HIF-1a is not increased in ade-
nocarcinoma cells is problematic with three possible
explanations. 1) That hypoxic conditions were insuffi-
cient in the adenocarcinoma cell lines while sufficient in
the gliomas to elicit activation of HIF-1a based on the
possibility that astrocytes arec o n s t i t u t i v e l ym o r es e n s i -
tive and responsive to hypoxia in keeping with their
function to protect neurons and this functionality carries
over to the glioma (malignant astrocytoma) tumors stu-
died. 2) HIF-1a levels were constitutively up regulated
(oncogenic) in the glioma lines independent of hypoxic
effects. In an effort to answer this question, we
2D→3D Survival Drivers
Cell Survival Cell Survival
Gene expression & cell
proliferation
Gene expression & cell 
proliferation
Motility, migration,
& invasion
Motility, migration, 
& invasion
FAK
Paxillin
Shc
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MAPK pathway MAPK pathway
p38(Thr180)
PI3K
TSC2(Thr1462)
GSK3αβ(ser21)
AKT pathway
RAF
ERK1/2
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CDK5
Cyclin B1
BCL-X
Β-Catenin 
CHK1
ATR
ATRIP
Src(Tyr416-418) Src(Tyr416-418)
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Figure 5 This is a cartoon of the shared partial pathways involved in the transition of > 50% of glioma and adenocarcinoma cell lines
from monolayer to 3D growth and are consistent with in situ tumors seeking to survive the more difficult 3D growth that will lead to
genetic stress and part of the angiogenesis cascade. The red color indicates the protein increased and the blue color that the protein
decreased.
Levin et al. Proteome Science 2012, 10:5
http://www.proteomesci.com/content/10/1/5
Page 8 of 13compared each protein across cell lines and between
glioma and adenocarcinoma groups from monolayer
conditions. We found only 3 proteins that had a coeffi-
cient of variation of > 0.5 and T-test p < 0.05, and they
were AKT(ser473), AK(Thr308) and HIF-1a;t h e yw e r e
higher in base value in the glioma lines than adenocarci-
noma lines by 4.7-, 3.0-, and 2.6-fold. Since the cell lines
were compared to themselves, with respect to change in
protein level, under the various “treatment” conditions
of 3D culture and hypoxia, the differences in absolute
level did not have an adverse effect on the data we
report in Figures 1, 2, 3 and 4). 3) The failure of HIF-1a
to increase with hypoxia in adenocarcinoma lines could
be these cell lines mediate the hypoxia response mainly
by HIF-2a orHIF-3a. Since we did not measure these
proteins in our studies, we cannot test this hypothesis.
Conclusion
We examined the proteins associated with each transi-
tion to see if there was clear involvement of specific
pathways. Our findings were mixed. The changes are
broad and extensive, not clearly concentrated in one
a r e a .D u r i n gt r a n s i t i o nf r o m2 Dt o3 Dg r o w t hw es e e
large changes at the protein level and AKT and MAPK
pathways are mainly activated to provide survival and
anticipated a need for angiogenesis in 3D. In hypoxia as
compared to normoxia, the mTOR pathway is down-
regulated. Also during hypoxia, when glioma cell lines
are compared to adenocarcinomas, we infer that gliomas
are much more responsive to hypoxia than adenocarci-
nomas as evident from the simultaneous apoptotic and
pro-survival pathway activation.
We wish our experiments had definitively exposed a
new therapeutic strategy for high-grade glioma and/or
adenocarcinomas. What we have learned, however, is
more tentative and incomplete. The mTOR pathways
appeared to be down regulated in hypoxia in the current
study and under conditions of starvation from our pre-
vious study. If mTOR pathways are normally down-regu-
lated in tumor hypoxia, drug inhibitors of the mTOR
pathway may not be a successful treatments for high-
grade gliomas as the target may already be depressed, a
conclusion supported by current clinical trials of mTOR
inhibitors in glioblastoma patients [32-35].
Our data are available on the web. We hope others
will look at our data and approach and make further
observations to develop better chemotherapy strategies
in the future.
Methods
Cell Lines
We used 11 established cell lines in this study. Six adeno-
carcinomas were comprised of three human breast cancer
cell lines (MCF7, MDA231, MDA468), gifts from Fran-
cisco Esteva (MD Anderson); a human pancreatic carci-
noma (MiaPaCa), a gift from Kapil Mehta (MD
Anderson); and two human ovarian carcinomas (OVCAR5
and SKOV3), purchased from the American Type Culture
Normoxia→Hypoxia Drivers
NCKIPSD
Cyclin B1
P70S6K
S6(Ser240)
S6(Ser235)
mTOR pathway
4EBP1(Ser65)
c-Myc
SMAD3(ser423)
Translation off Transcription off G2-M arrest
Motility, migration & 
stress fiber formation
Figure 6 This is a cartoon of the partial shared pathways involved in the transition of > 50% of glioma and adenocarcinoma cell lines
from normoxia to hypoxia. The red color indicates the protein increased and the blue color that the protein decreased.
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Page 9 of 13Collection (Manassas, VA). Five high-grade glioma lines
were comprised of U87, U251HF, and SNB19, bought
from the American Type Culture Collection, and LNZ308
and LN229, gifts from Oliver Bogler (MD Anderson).
Cells were maintained in Dulbecco’s modified Eagle’s
medium: nutrient mixture F-12 (DMEM/F-12; Invitrogen,
Carlsbad, CA) supplemented with10% fetal bovine serum
(Sigma-Aldrich, St. Louis, MO) and 1% penicillin-strepto-
mycin antibiotic (Invitrogen).
Normoxia and Relative Hypoxia Conditions
For normoxia experiments, 2D and 3D cultured cells
were incubated in a humidified incubator with constant
supply of 5% CO2 at 37°C (21% oxygen). 2D and 3D
cultures were grown under conditions of relative
h y p o x i au s i n gt h eI n c u b a t o rS u b c h a m b e rC u l t u r eS y s -
tem with the ProOx 110 oxygen controller (BioSpherix,
Lacona, NY) that senses oxygen inside the chamber and
maintains it at the set level that was, in our experiments,
1% oxygen for relative hypoxia (for 24 hours).
Antibodies and Validation
The antibodies used are listed in Additional file 3, Table
S1. To ensure that our antibodies were of sufficient
quality, we used a denatured protein array and con-
firmed the specificity of the antibodies using Western
blotting. Antibodies with only a single or dominant
band on Western blotting were further assessed by
direct comparison with RPPA using cell lines for differ-
ential protein expression, or they were modulated with
ligands/inhibitors or siRNA for phosphoproteins or
structural proteins, respectively. Only antibodies with
Pearson correlations > 0.7 between RPPA and Western
blotting were considered “validated” a n du s e di nt h i s
RPPA study. Antibodies were further assessed for speci-
ficity and quantification using phosphopeptides and
non-phosphopeptides arrayed on nitrocellulose-coated
s l i d e s ;t h o s ew i t has e c o n dn o n - d o m i n a n tb a n dt h a t
could be rationalized and were otherwise consistent in
terms of RPPA linearity they were used “with caution.”
As can be appreciated from the Numerical Preproces-
sing section below, the original study was initiated with
187 proteins to cover a large part of the known pro-
teome, but because of technical issues, we were only
able to study 121 different proteins in the RRPA.
Preparation of Cell Lysates
The techniques used for the 2D studies were similar to
those published previously [1,36], however, the isolation
of cells from the 3D medium is described in detail here.
2D Studies
Briefly, less than 10
6 cells/mL were plated in flasks, har-
vested in exponential growth at about 80% confluence,
and harvested using 0.25% trypsin. Cells were counted
with a Vi-Cell Counter (Beckman Coulter, Brea, CA),
and 5 × 10
6 cells were transferred to six-well plates (35-
mm diameter, 5-ml volume) that were grown for 24 h
at 37°C in 5% CO2 and 20% O2 [1]. Cells were similarly
cultured in parallel for 24 h in a 1% O2 hypoxic envir-
onment. Duplicate cultures were performed for each
treatment. After 24 h, cells were washed in phosphate-
buffered saline and lysed in 1% Triton X-100, 50 nM
Glioma Hypoxia Drivers
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Figure 7 This is a cartoon of the partial pathways involved in the transition of > 50% of glioma cell lines from normoxia to hypoxia.
The red color indicates the protein increased and the blue color that the protein decreased.
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Page 10 of 13HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2,1m M
EGTA, 100 mM NaF, 10 mM sodium pyrophosphate, 1
mM Na3VO4, and 10% glycerol containing freshly added
protease and phosphatase inhibitors. Cellular proteins
were denatured by 1% sodium dodecyl sulfate (with ß-
mercaptoethanol) and diluted in five serial 1:2 dilution
steps using dilution buffer (lysis buffer containing 1%
sodium dodecyl sulfate).
3D Studies
We used the AlgiMatrix 3D Culture System six-well kit
(Invitrogen), which is an animal origin-free bioscaffold
that facilitates 3D cell culture. 2 × 10
4 cells in exponen-
tial growth were pipetted into six-well plates in 5 mL of
medium (DMEM/F-12) and inoculated directly into the
sterile microtiter plates preloaded with lyophilized algi-
nate sponge that had been formulated using USP-grade
raw material from brown seaweed, and each plate incu-
bated at 37°C in an atmosphere of 5% CO2 and 20% O2
(i.e., normoxia) to allow the cells to form spheroids. The
cell lines grew similarly except for the ovarian cancer
cell lines that grew a bit slower.
On day 5, we transferred half the plates to the hypoxia
chamber mentioned earlier and allowed them to grow
for 24 h in relative hypoxia while the remaining half
served as normoxia controls. To harvest spheroids after
24 h of hypoxia (i.e., on day 6), we followed the tri-
sodium method described in the AlgiMatrix protocol.
Briefly, 5 mL of pre-warmed iso-osmolar tri-sodium
citrate solution was added to each well and incubated
for 10 min at 37°C. The solution was prepared by dilut-
ing 55 mM tri-sodium citrate solution from 1 M stock
solution, adding 1 g/L glucose, adjusting the osmolarity
using 100 g/L NaCl solution, and adjusting the pH with
1 M citric acid solution to a pH of 7.2-7.4. After 10
min, the sponge biodegraded into the solution and the
contents of each well was pipetted into a 15-mL centri-
fuge tube. To the tube, 5 mL of the same tri-sodium
citrate solution was added, and the mixture was centri-
fuged for 7 min at 400 × g. The supernatant was
removed, the pellet washed in phosphate-buffered saline
to remove any remaining medium, and the pellet lysed
using lysis buffer. The sample was then denatured, seri-
ally diluted, and arrayed on slides as in the 2D studies.
We manually isolated spheroids and determined the
viability of single cells by adding them to 2 mL of tryp-
sin-EDTA in a 15-mL tube, incubating at 37°C for a few
minutes, agitating the tube for 15-20 min, and counting
using the Vi-Cell cell viability analyzer (Beckman-Coul-
ter). In all cases, the proportion of viable cells was
greater than 90%.
Array Assembly and Printing
Array assembly and printing were done as previously
described. [37] In addition to the sample spots (2D
normoxia, 2D hypoxia, 3D normoxia, and 3D hypoxia
samples), each slide also included spots corresponding
to positive and negative controls prepared from mixed
cell lysates and dilution buffer, respectively. For quantifi-
cation, protein lysates were passed through five serial 1:2
dilution steps, spotted in triplicate, and arrayed in 384-
well plates (Genetix, Boston, MA). Samples were printed
onto nitrocellulose-coated glass slides (FAST Slides,
Schleicher & Schuell BioScience, Inc. USA, Keene, NH)
using an Aushon BioSystems 2470 Arrayer (Aushon Bio-
Systems, Inc., Burlington, MA) with 175-μmp i n sa n da
soft-touch deposition technology. For each triple, one
series was located in the middle of the array and the
o t h e rt w ow e r es p l i to nb o t hs i d e sa n da r r a n g e di nt h e
reverse orientation, allowing us to estimate and correct
for any spatial trends in intensity. To correct for stain-
ing, background, and loading variation across (array)
slides, a positive control (a mixture of 12 cell lines here-
after called the “pooled control”) and a lysate buffer
negative control were printed at the end of each cell
line sample row, creating a grid across the whole slide.
Antibody Detection and Array Staining
A n t i b o d ya n da r r a ys t a i n i n gw e r ed o n ea sp r e v i o u s l y
described [37,38]. Briefly, slides were probed with pri-
mary antibody plus a biotin-conjugated secondary anti-
body. The signal was amplified using a DakoCytomation-
catalyzed system (Dako, Copenhagen, Denmark) and
visualized by the diaminobenzidine colorimetric reaction.
Slides were incubated for 15 min in biotin-blocking solu-
tion to block endogenous peroxidase, avidin, and biotin
prior to incubating slides in protein block at 4°C over-
night. Primary antibodies in concentrations from 1:100 to
1:2000 were added to the slides and allowed to remain for
1-2 h with frequent slide agitation to insure mixing on
the slide (see supplement table S-1 for dilutions and
manufacturers of antibodies). A biotinylated secondary
antibody (anti-mouse or -rabbit), diluted 1:10000-1:20000
and used as a starting point for signal amplification, was
added and allowed to remain in contact with the cells for
1 h. Subsequently, array slides were incubated using the
Dako Signal Amplification System using a catalyzed
reporter deposition of substrate to amplify the signal of
the primary antibody. Slides were incubated in streptavi-
din-biotin-peroxidase and biotinyl tyramide/hydrogen
peroxide reagents for 15 min each with washing in
between the two incubations; 3,3’-diaminobenzidine tet-
rachloride was cleaved by tyramide-bound horseradish
peroxidase, giving a stable brown precipitate.
Analysis of RPPA Data
Experimental Design and Deviations
We studied 11 cell lines with two replicates under the
four growth conditions resulting from combining 2D
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Page 11 of 13and 3D under normoxia and relative hypoxia, which
would have ideally yielded 88 samples for measurement.
Unfortunately, because of technical problems, there was
only one replicate for LNZ308 in 3D under normoxia
and hypoxia and one replicate for U87 in 3D in nor-
moxia. Thus, we studied only 85 samples. Fortunately,
the 41 pairs of exact replicates that did work are ade-
quate to let us estimate the scale of technical variation,
which is much smaller (variance 0.0053) than the var-
iance 0.4615 for the cell line, growth condition, and
treatment effects studied. Consequently, the replicate to
replicate variation is sufficiently small and stable across
our experiments relative to other sources of error that
keeping the small number of samples without replicates
will not lead to any distortion of the data.
Numerical Preprocessing
These samples were examined using 187 antibodies in
RPPAs produced by the lead author’s laboratory. Array
images were produced using ImageQuant software (GE
Healthcare, Waukesha, WI), and individual spot values
were summarized using the MicroVigene RPPA module
(VigeneTech, Carlisle, MA). After preprocessing was
done, we used the R package SuperCurve (available at
http://bioinformatics.mdanderson.org/Software/
OOMPA) to summarize each five-step dilution series
into one log2 scale (EC50) protein concentration value.
T h ea l g o r i t h mu s e df i t saj o i nt four-parameter logistic
model [39]. Values for 153 of these arrays passed signal-
to-noise filters assessed on control samples, giving the
85-by-153 data matrix we received from the core facility.
Rows of this matrix (samples) were centered on the
median to adjust for potential differences in sample
loading. Correlations between replicate spotting’so ft h e
same samples on each array were also checked for con-
sistency; we retained only the 124 (121 different proteins
with 3 duplicates listed by different names) that showed
correlations in excess of 0.5. Clustering and other
exploratory data analysis showed that labels for samples
63 (MDA468-3D Hypoxia) and 83 (MDA231-3D
Hypoxia) had accidentally been swapped; we corrected
this.
Statistical Analysis
We used three-way ANOVAs, protein by protein, to
model the log2 expression values produced by the
RPPAs. We included terms for treatment (hypoxia or
normoxia), growth conditions (2D or 3D), and cell line
of origin. We also included a term to account for poten-
tial interaction between treatment and medium.
To account for multiple testing, we fit distributions of
p-values for each contrast with beta-uniform mixture
(BUM) models
5 and chose cutoffs to target false discov-
ery rates (FDRs) of 5% and 1%.
To determine what changes were “robust,” we tricho-
tomized residual terms for each effect (after correcting
for others) by assigning scores of 1 (top 25%), -1 (bot-
tom 25%), and 0 (all others), and summed these values
by cell line or antibody, which is an approach we found
useful in an earlier study [1]. We also used these sums
to look for differences between gliomas and adenocarci-
nomas. Full details of our analyses (including data and
code) are available from http://bioinformatics.mdander-
son.org/Supplements/LevinHypoxia/
Additional material
Additional file 1: This file contains is from the quantile matrix of
trichotomized values for 3D-2D values used in Figures 2 and 3 of
the paper.
Additional file 2: This file contains is from the quantile matrix of
trichotomized values for hypoxia-normoxia values used in Figure 4
of the paper.
Additional file 3: Table S1. Descriptions of 121 Distinct and 3 Duplicate
Antibodies Used in Our RPPA Studies. BCL-XL, collagen VI, and Src
(Tyr416/418), were used in duplicate, bringing the total number of
antibodies studied in the RPPA to 124. Phosphorylation sites are
indicated in parentheses.
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